Molecular Insight Pharmaceuticals, Inc.

Cornell University

The General Hospital Corporation

Biostream, Inc.

Biostream Therapeutics, Inc.

Other

The Jmde Trust

Molecular Insight Pharmaceuticlas, Inc.

John W Babich

Craig N Zimmerman

Kevin P Maresca

John L Joyal

Genliang Lu

Shawn Hillier

James M Kelly

Shashikanth Ponnala

Alejandro Amor-Coarasa

David R Elmaleh

John Marquis

Jian-cheng Wang

Alan J Fischman

Justin Wilson

Nikki Thiele

Miles P Smith

Timothy M Shoup

Jon Zubieta

Grant Bonavia

Paul C Zamecnik

Robert N Hanson

Eliezer Rapaport

James F Kronauge

Chris Barone

James Kronauge

Kevin B Maresca

Jian-Cheng Wang

Craig Zimmerman

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.

Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies

The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue viaF-labeled peptide ligands disclosed herein.

F-labeled peptide ligands useful in PET and Cerenkov luminescene imaging

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:

Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer

The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II or pharmaceutically acceptable salts thereof. The present technology is especially well-suited for use in treating prostate cancer.

Double targeted constructs to affect tumor kill

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Triazine based radiopharmaceuticals and radioimaging agents

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof. 

Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen ('PSMA') where the compounds are represented by the following:   

A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.

Organ protection in PSMA-targeted radionuclide therapy of prostate cancer

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA. 

Compounds of Formula (Ia) wherein R is a C-Csubstituted or unsubstituted aryl, a C-Csubstituted or unsubstituted heteroaryl, a C-Csubstituted or unsubstituted alkyl or &#x2014;NR'R&#x2032;,

Heterodimers of glutamic acid

Growing community of inventors

Cambridge, MA, United States of America

John W Babich